|
Post by Clement on Oct 14, 2022 7:19:03 GMT -5
finance.yahoo.com/news/united-therapeutics-feature-clinical-data-100000246.htmlUnited Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2022 Annual Meeting SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., October 14, 2022--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that three presentations and two posters across its commercial and development portfolio will be presented at the CHEST 2022 Annual Meeting hosted by the American College of Chest Physicians taking place October 16-19, 2022, in Nashville, Tennessee. In addition, United Therapeutics is sponsoring the CHEST Women & Pulmonary Luncheon and will host an educational symposium on pulmonary hypertension associated with interstitial lung disease (PH-ILD), both on Monday, October 17, 2022. "CHEST 2022 will provide us with the opportunity to update the pulmonology and pulmonary hypertension communities on long-term data from the INCREASE and FREEDOM-EV open-label extension studies, and to present a concerning real-world claims data analysis describing a potential gap in optimal initial combination therapy for pulmonary arterial hypertension patients," said Andrew Nelsen, Pharm.D., Vice President, Global Medical Affairs at United Therapeutics.
|
|
|
Post by cppoly on Oct 18, 2022 8:02:40 GMT -5
Anyone know what happened / what's happening at the CHEST annual meeting?
|
|
|
Post by MnkdWASmyRtrmntPlan on Oct 18, 2022 8:27:03 GMT -5
Drug: Inhaled TYVASO (treprostinil) - (PERFECT) Indication: Pulmonary Hypertension associated with chronic obstructive pulmonary disease (PH-COPD) Stage: Phase 3 Catalyst Date: 10/18/2022 Catalyst: Phase 3 trial ongoing, noted February 24, 2022. Phase 3 Long-Term safety and tolerability data to be presented at the CHEST 2022 on October 18, 2022.
|
|
|
Post by MnkdWASmyRtrmntPlan on Oct 18, 2022 9:12:35 GMT -5
10/14/2022 United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2022 Annual Meeting Data from the INCREASE open label extension study of Tyvaso® detail its long-term safety and tolerability in pulmonary hypertension associated with interstitial lung disease
Data from the FREEDOM-EV open label extension study of Orenitram® details an association with improved survival and, separately, its effects as part of a combination therapy regimen in patients with pulmonary arterial hypertension
Real-world analysis to describe initial combination treatment strategies in pulmonary arterial hypertension
United Therapeutics is sponsoring the CHEST Women & Pulmonary Luncheon and hosting a PH-ILD educational symposium
United Therapeutics Corporation (NASDAQ:UTHR), a public benefit corporation, today announced that three presentations and two posters across its commercial and development portfolio will be presented at the CHEST 2022 Annual Meeting hosted by the American College of Chest Physicians taking place October 16-19, 2022, in Nashville, Tennessee. In addition, United Therapeutics is sponsoring the CHEST Women & Pulmonary Luncheon and will host an educational symposium on pulmonary hypertension associated with interstitial lung disease (PH-ILD), both on Monday, October 17, 2022.
"CHEST 2022 will provide us with the opportunity to update the pulmonology and pulmonary hypertension communities on long-term data from the INCREASE and FREEDOM-EV open-label extension studies, and to present a concerning real-world claims data analysis describing a potential gap in optimal initial combination therapy for pulmonary arterial hypertension patients," said Andrew Nelsen, Pharm.D., Vice President, Global Medical Affairs at United Therapeutics. "We're also thrilled to sponsor two important events at this congress: the Women & Pulmonary Luncheon where women in chest medicine can gain insights on how to advance their careers in this critically important field, and a symposium detailing the screening-to-diagnosis-to-early treatment journey for PH-ILD."
Oral Presentations include:
Rapid fire original investigation presentation, Monday, October 17, 12:23 - 12:27 PM CT: Rapid Area 1B/4104 – Oral Treprostinil as Part of a Triple-Therapy Regimen for Pulmonary Arterial Hypertension: Analysis from the FREEDOM-EV Open-Label Extension. Presented by Jean Elwing, M.D., FCCP, University of Cincinnati.
Rapid fire original investigation presentation, Monday, October 17, 12:43 - 12:47 PM CT: Rapid Area 1B/4104 – Initial Treatment Strategy in Patients with Pulmonary Arterial Hypertension Using Two Large US Administrative Claims Databases. Presented by Sandeep Sahay, M.D., FCCP, Houston Methodist Hospital.
Rapid fire original investigation presentation, Wednesday, October 19, 11:31 - 11:35 AM CT: Rapid Area 2A/4142 – The Burden of Illness in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease in US Administrative Claims Data. Presented by James Klinger, M.D., FCCP, Alpert Medical School of Brown University.
Posters include:
Pulmonary arterial hypertension (PAH) abstract poster, Tuesday, October 18, 1:30 - 2:30 PM CT: 4218/2070 – Long-Term Safety and Tolerability of Inhaled Treprostinil in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease in the INCREASE Open-Label Extension. Presented by Jean Elwing, M.D., FCCP, University of Cincinnati.
PAH abstract poster, Tuesday, October 18, 1:30 - 2:30 PM CT: 4218/2071 – Oral Treprostinil Treatment is Associated with Improved Survival in Pulmonary Arterial Hypertension Participants in FREEDOM-EV and the FREEDOM-EV Open-Label Extension Study. Presented by R. James White, M.D., Ph.D., University of Rochester.
Sponsored events include:
The CHEST 2022 Women & Pulmonary Luncheon, Monday, October 17, 12:00 - 1:30 PM CT, featuring Janet Bickel, a noted career and leadership development coach who will provide tips on how to advance one's career through her presentation, "You Are the CEO of Your Own Career." The luncheon will be held at the Music City Convention Center, Karl Dean Grand Ballroom A1.
PH in ILD: The Clouds Are Clearing, Monday October 17, 6:30 PM CT, featuring Jean Elwing, M.D., FCCP, University of Cincinnati; Lisa Lancaster, M.D., FCCP, Vanderbilt University; and Sandeep Sahay, M.D., FCCP, Houston Methodist Hospital. The symposium will be held at the Omni Nashville Hotel, Legends Ballroom E-G.
|
|
|
Post by jkendra on Oct 19, 2022 7:56:09 GMT -5
|
|
|
Post by jkendra on Oct 19, 2022 7:57:35 GMT -5
|
|
|
Post by Clement on Oct 24, 2022 9:39:50 GMT -5
Last year, UTHR reported Q3 on Nov 3.
|
|
|
Post by jkendra on Oct 26, 2022 6:01:33 GMT -5
|
|
|
Post by jkendra on Nov 1, 2022 7:38:30 GMT -5
www.bakersfield.com/ap/news/united-therapeutics-corporation-to-present-at-the-credit-suisse-31st-annual-healthcare-conference/article_8e6d0ee6-77b9-5bbf-8890-a4f0d636c2f2.htmlUnited Therapeutics Corporation to Present at the Credit Suisse 31st Annual Healthcare ConferenceSILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Nov 1, 2022--
United Therapeutics Corporation (Nasdaq: UTHR ) announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s business during a fireside chat session at the Credit Suisse 31 st Annual Healthcare Conference in Los Angeles.
The session will take place on Tuesday, November 8, 2022, from 12:50 p.m. to 1:20 p.m., Pacific Standard Time, and can be accessed via a live webcast on the United Therapeutics website at ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed at the same location for 90 days.
|
|
|
Post by jkendra on Nov 1, 2022 7:43:21 GMT -5
www.businesswire.com/news/home/20221031005165/en/United-Therapeutics-Announces-Top-Line-Data-From-the-EXPEDITE-Study-of-Remodulin-Induction-Prior-to-Orenitram-TherapyUnited Therapeutics Announces Top Line Data From the EXPEDITE Study of Remodulin Induction Prior to Orenitram TherapyOctober 31, 2022 06:00 AM Eastern Daylight TimeSILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that a preliminary analysis of the EXPEDITE study in patients suffering from World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) demonstrated that 79% of patients in the study achieved an Orenitram (treprostinil) extended-release tablet dose of at least 4 mg three times daily (TID), for a 12 mg total daily dose at 16 weeks, after an up to eight week induction treatment period with Remodulin (treprostinil) injection. Detailed study results will be made available through scientific disclosure at upcoming medical conferences and in peer-reviewed publications.The EXPEDITE trial represents a framework to get carefully selected PAH patients on clinically impactful oral doses of a critical class of medication safely and so much more timely,” said John Kingrey, M.D., director of the Pulmonary Hypertension center at INTEGRIS Baptist Medical Center. “I’m so pleased with how my patients did with this approach, as it really did expedite (pun intended!) their path to achieving increased prostacyclin dosages.”“We’re delighted with the preliminary results from the EXPEDITE study, which provided patients a way to reach efficacious doses in a shorter period of time without having to commit to long-term pump therapy,” said Meredith Broderick, Pharm.D., J.D., Senior Director of Global Medical Affairs at United Therapeutics. “Along with our other phase 4 studies, EXPEDITE demonstrates our commitment to optimize available treatment options in order to help PAH patients better manage their disease.”In EXPEDITE, patients enrolled in the study achieved a mean total daily Orenitram dose of 16.4 mg at 16 weeks with 79% of study subjects reaching the study’s primary endpoint of a 12 mg total daily dose. Secondary outcome measures included six-minute walk distance (6MWD); the cardiac biomarker N-terminal pro-brain natriuretic peptide (NT-proBNP); WHO functional classification; echocardiography; risk scores; and health related quality of life, as assessed using the emPHasis-10 questionnaire.A previous real world dosing analysis showed an average Orenitram dose of approximately 6 mg daily after 16 weeks without the induction protocol studied by the EXPEDITE study1. In addition, scientific literature shows that higher doses of treprostinil have been associated with better outcomes for patients with PAH2.Treatment with Orenitram, three times daily, was well tolerated and the safety profile was consistent with previous Orenitram studies in PAH. In the study, several well-known treprostinil adverse events such as headache, nausea, and vomiting tended to improve after transition to Orenitram from Remodulin.
|
|
|
Post by neil36 on Nov 1, 2022 17:44:00 GMT -5
According to Yahoo! Finance, UTHR earnings estimate for tomorrow is $3.89 per share with an average estimated revenue of $493.2 million
Previous quarter Tyvaso sales were $201 million
|
|
|
Post by neil36 on Nov 2, 2022 5:06:41 GMT -5
According to Yahoo! Finance, UTHR earnings estimate for tomorrow is $3.89 per share with an average estimated revenue of $493.2 million Previous quarter Tyvaso sales were $201 million UTHR revenues $516 million ($493 expected)
Earnings per share: $4.91 per diluted share ($3.89 expected)
Tyvaso (and DPI) sales: $257.7 million (up from $201 million last quarter)
|
|
|
Post by hellodolly on Nov 2, 2022 5:58:36 GMT -5
According to Yahoo! Finance, UTHR earnings estimate for tomorrow is $3.89 per share with an average estimated revenue of $493.2 million Previous quarter Tyvaso sales were $201 million UTHR revenues $516 million ($493 expected)
Earnings per share: $4.91 per diluted share ($3.89 expected)
Tyvaso (and DPI) sales: $257.7 million (up from $201 million last quarter)That's double digit +20% growth of Tyvaso from the last quarter.
|
|
|
Post by jkendra on Nov 2, 2022 7:53:03 GMT -5
bethesdamagazine.com/2022/11/02/united-therapeutics-buys-another-building-near-its-downtown-silver-spring-headquarters/United Therapeutics buys another building near its downtown Silver Spring headquarters
United Therapeutics Corp. continues to snap up properties near its downtowns Silver Spring headquarters — but has largely remained quiet about its long-term plans for the additional space. The local drugmaker most recently bought a building at 8905 Fairview Road for $11.85 million, according to Montgomery County property records. The transaction, which closed Oct. 5, also includes a parking lot across the street. [Washington Business Journal]
|
|
|
Post by MnkdWASmyRtrmntPlan on Nov 2, 2022 9:13:38 GMT -5
United Therapeutics 3RD Qtr Earnings call was kick-ass this morning. UTHR is up $14 this morning. DPI is gangbusters and they are hitting on all 8 cylinders. Talk of DPI was very positive - previously postulated to eventually be 50% of Tyvaso sales, but it is already there (after 4 months). It took MNKD longer than I expected to start climbing as a result of that call this morning, but it is taking off now too. I will bet that MNKD will hit $4.00 before next Tuesday's call.
|
|